Perrigo (PRGO) Non Operating Income (2023 - 2026)
Perrigo's (PRGO) quarterly Non Operating Income came in at -$40.8 million in Q1 2026, down 4.62% year-on-year from -$42.8 million in Q1 2025, and up 5.77% on a QoQ basis from -$43.3 million in Q4 2025.
Perrigo (PRGO) Non Operating Income (2023 - 2026) Analysis & Trends
Perrigo (PRGO) has 4 years of Non Operating Income data on file, last reported at -$40.8 million in Q1 2026.
- On a quarterly basis, Non Operating Income fell 4.62% year-over-year to -$40.8 million in Q1 2026; TTM through Mar 2026 was -$164.3 million, a 10.61% increase from a year earlier, with the FY2025 full-year figure at -$162.5 million, up 13.47% from the prior year.
- Non Operating Income for Q1 2026 stood at -$40.8 million, up from -$43.3 million in the prior quarter.
- Over the last five years, Non Operating Income for PRGO reached as high as -$39.0 million in Q1 2025 and fell as low as -$57.6 million in Q3 2024.
- Historically, Non Operating Income has averaged -$43.4 million across 4 years, with a median of -$43.0 million in 2024.
- Across the five-year window, Non Operating Income slumped 32.41% in 2024 and rose 29.51% in 2025, its largest moves.
- Year by year, Non Operating Income stood at -$42.7 million in 2023, then fell by 0.94% to -$43.1 million in 2024, then slipped by 0.46% to -$43.3 million in 2025, then increased by 5.77% to -$40.8 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were -$40.8 million in Q1 2026, -$43.3 million in Q4 2025, and -$40.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | -40.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -40.80 Mn |
| Dec 31, 2025 | -43.30 Mn |
| Sep 27, 2025 | -40.60 Mn |
| Jun 28, 2025 | -39.60 Mn |
| Mar 29, 2025 | -39.00 Mn |
| Dec 31, 2024 | -43.10 Mn |
| Sep 28, 2024 | -57.60 Mn |
| Jun 29, 2024 | -44.10 Mn |
| Mar 30, 2024 | -43.00 Mn |
| Dec 31, 2023 | -42.70 Mn |
| Sep 30, 2023 | -43.50 Mn |
| Jul 1, 2023 | -44.00 Mn |